

**COPS5 Antibody**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

<b>Applications:</b> W, IP	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 37	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #Q92905	<b>Entrez-Gene Id:</b> 10987
-------------------------------	--------------------------------	-----------------------------------	------------------------	----------------------------------	-------------------------------	---------------------------------

**Product Usage Information****Application**

Western Blotting  
Immunoprecipitation

**Dilution**

1:1000  
1:50

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

**Specificity/Sensitivity**

COPS5 Antibody recognizes endogenous levels of total COPS5 protein. This antibody does not cross-react with PSMD14/POH1.

**Species predicted to react based on 100% sequence homology**

Xenopus, Zebrafish, Bovine, Dog, Pig, Horse

**Source / Purification**

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino-terminus of human COPS5 protein. Antibodies are purified by protein A and peptide affinity chromatography.

**Background**

The COP9 Signalosome (CSN) is a ubiquitously expressed multiprotein complex that is involved in a vast array of cellular and developmental processes, which is thought to be attributed to its control over the ubiquitin-proteasome pathway. Typically, the CSN is composed of eight highly conserved subunits (CSN1-CSN8), each of which is homologous to one of the eight subunits that form the lid of the 26S proteasome particle, suggesting that these complexes have a common evolutionary ancestor (1). CSN was first identified in *Arabidopsis thaliana* mutants with a light-grown seedling phenotype when grown in the dark (2-4). The subsequent cloning of the constitutive morphogenesis 9 (cop9) mutant from *Arabidopsis thaliana* was soon followed by the biochemical purification of the COP9-containing multiprotein complex (4). It is now widely accepted that the CSN directly interacts with cullin-RING ligase (CRL) families of ubiquitin E3 complexes, and that CSN is required for their proper function (5). In addition, CSN may also regulate protein homeostasis through its association with protein kinases and deubiquitinating enzymes. Collectively, these activities position the CSN as a pivotal regulator of the DNA-damage response, cell-cycle control, and gene expression (1).

COPS5/CSN5/Jab1 (c-Jun activation domain-binding protein-1) was originally identified as a transcriptional coactivator of c-Jun and subsequently discovered to be a fifth component and integral part of the CSN (6). As the catalytic center of the CSN, COPS5 is able to integrate multiple functions of the CSN complex such as cell-cycle control, transcription, and DNA-damage response by regulating the activity of CRLs through deneddylation of cullins (7). Indeed, COPS5 harbors a Mpr1-Pad1-N-terminal (MPN) domain with an embedded Jab1/CSN5 MPN domain metalloenzyme (JAMM) motif that is essential for the CSN isopeptidase activity responsible for deneddylation of CRLs. COPS5 is an evolutionarily conserved 38 kDa protein in humans, mice, fission yeast, and plants, which suggests that it is critical to cell survival and proliferation. A role for COPS5 as a positive regulator of cellular proliferation is supported by evidence that it functionally inactivates several key tumor suppressors such as p53, RUNX3, Smad4, and p27<sup>Kip1</sup> through altered subcellular localization, degradation, and deneddylation (8-12). These findings are underscored by the observation that COPS5 overexpression has been identified in a number of different tumor types and has been implicated in the initiation and progression of several types of cancer (13). Moreover, COPS5-deficient mice display an embryonically lethal phenotype highlighted by elevated expression of COPS5 targets such as p53 and p27 (14,15).

**Background References**

1. Wei, N. and Deng, X.W. (2003) *Annu Rev Cell Dev Biol* 19, 261-86.
2. Kwok, S.F. et al. (1996) *Plant Physiol* 110, 731-42.
3. Wei, N. et al. (1994) *Cell* 78, 117-24.
4. Chamovitz, D.A. et al. (1996) *Cell* 86, 115-21.
5. Cope, G.A. and Deshaies, R.J. (2003) *Cell* 114, 663-71.
6. Claret, F.X. et al. (1996) *Nature* 383, 453-7.
7. Wei, N. et al. (2008) *Trends Biochem Sci* 33, 592-600.
8. Bech-Otschir, D. et al. (2001) *EMBO J* 20, 1630-9.

9. Oh, W. et al. (2006) *J Biol Chem* 281, 17457-65.
  10. Wan, M. et al. (2002) *EMBO Rep* 3, 171-6.
  11. Tomoda, K. et al. (2002) *J Biol Chem* 277, 2302-10.
  12. Kim, J.H. et al. (2009) *J Cell Biochem* 107, 557-65.
  13. Shackleford, T.J. and Claret, F.X. (2010) *Cell Div* 5, 26.
  14. Tian, L. et al. (2010) *Oncogene* 29, 6125-37.
  15. Tomoda, K. et al. (2004) *J Biol Chem* 279, 43013-8.
- 

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween@ 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**W:** Western Blotting **IP:** Immunoprecipitation

**Cross-Reactivity Key**

**H:** Human **M:** Mouse **R:** Rat **Mk:** Monkey

**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

**Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.